Betaloc IV

Χώρα: Νέα Ζηλανδία

Γλώσσα: Αγγλικά

Πηγή: Medsafe (Medicines Safety Authority)

Δραστική ουσία:

Metoprolol tartrate 1 mg/mL;  

Διαθέσιμο από:

AstraZeneca Limited

INN (Διεθνής Όνομα):

Metoprolol tartrate 1 mg/mL

Δοσολογία:

1 mg/mL

Φαρμακοτεχνική μορφή:

Solution for injection

Σύνθεση:

Active: Metoprolol tartrate 1 mg/mL   Excipient: Sodium chloride Water for injection

Μονάδες σε πακέτο:

Ampoule, glass, 5 mL, 5 dose units

Kατηγορία:

Prescription

Τρόπος διάθεσης:

Prescription

Κατασκευάζεται από:

Ipca Laboratories Limited

Θεραπευτικές ενδείξεις:

Betaloc IV is indicated for the following indications: · Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · Suspected or definite myocardial infarction.

Περίληψη προϊόντος:

Package - Contents - Shelf Life: Ampoule, glass, 5 mL - 5 dose units - 60 months from date of manufacture stored at or below 25°C protect from light

Ημερομηνία της άδειας:

1981-08-28

Αρχείο Π.Χ.Π.

 
Betaloc IV Data Sheet 050411 
Copyright 
1
NEW ZEALAND DATA SHEET 

NAME OF MEDICINE 

B
ETALOC 
IV 
metoprolol tartrate 1 mg/mL injection 

PRESENTATION 

Ampoule – a clear, colourless liquid free from foreign particles
containing 5 mL of 1 mg/mL 
metoprolol tartrate. 

USES 

ACTIONS 
Metoprolol is a beta
1
-selective beta-blocker, ie. it blocks beta
1
–receptors at doses much 
lower than those needed to block beta
2
-receptors. 

Metoprolol has an insignificant membrane-stabilising effect and does
not display partial 
agonist activity. 

Metoprolol reduces or inhibits the agonistic effect on the heart
of catecholamines (which are 
released during physical and mental stress).  This
means that the usual increase in heart 
rate, cardiac output, cardiac contractility
and blood pressure, produced by the acute increase 
in catecholamines, is reduced by metoprolol. 

During high endogenous adrenaline levels
metoprolol interferes much less with blood 
pressure control than non-selective beta-blockers. 

When mandatory, metoprolol , in combination with a beta
 2
-agonist, may be given to patients 
with symptoms of obstructive pulmonary disease.  When given
together with a beta
2
-agonist, 
metoprolol in therapeutic doses interferes less than non-selective
beta-blockers with the 
beta
2
-mediated bronchodilation  caused by the beta
2
-agonist. 

Metoprolol interferes less with insulin release and carbohydrate
metabolism than do non-
selective beta-blockers. 

Metoprolol interferes much less with the cardiovascular response
to hypoglycaemia than do 
non-selective beta-blockers.  

Short term studies have shown that metoprolol may cause a slight
increase in triglycerides 
and a decrease in free fatty acids in the blood.  In some cases, a
small decrease in the high 
density lipoproteins (HDL) fraction has been observed, although to a
lesser extent than that 
following non-selective beta-blockers.  Howe